Search

Displaying results 141 - 150 of 6970 in total
  1. Drug

    SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)

    go.drugbank.com/drugs/DB18705
    Approved

    [A262551] It is produced using recombinant DNA technology in CHO cell lines and is marketed by Hipra Human Health S.L. for the European market. … [L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907]

    Synonyms: SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)
  2. Drug

    Piperacillin

    go.drugbank.com/drugs/DB00319
    ApprovedInvestigational

    Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.

    Mixtures: PIPTAZ-AFT POWDER FOR SOLUTION FOR INJECTION 4.5G/VIAL, SALATAZ POWDER FOR SOLUTION FOR INJECTION/INFUSION 4.5G/VIALCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Avibactam

    go.drugbank.com/drugs/DB09060
    ApprovedInvestigational

    As there is limited clinical safety and efficacy data, Avycaz should be reserved for patients over 18 years old who have limited or not alternative treatment options. … This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract

    Mixtures: Zavicefta (Ceftazidime 2g/Avibactam 0.5g) Powder for Concentrate for Solution for Infusion, Emblaveo (Avibactam 0.5g/ Aztreonam 1.5g) Powder for concentrate for solution for infusionProducts: ZAVICEFTA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 2G/0.5G
  4. Drug

    Benzoic acid

    go.drugbank.com/drugs/DB03793
    ApprovedInvestigational

    Recent research shows that sodium benzoate may be beneficial as an add-on therapy (1 gram/day) in schizophrenia. Total Positive and Negative Syndrome Scale scores dropped by 21% compared to placebo. … As the sodium salt form, sodium benzoate is used as a treatment for urea cycle disorders due to its ability to bind amino acids.

    Mixtures: REXOM WINACOL SYRUP FOR CHILDREN, WOODS PEPPERMINT COUGH SYRUP FOR CHILDRENCategories: Tests for Gastric Secretion
  5. Drug

    Acetazolamide

    go.drugbank.com/drugs/DB00819
    ApprovedInvestigationalVet approved

    One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizur...

    Products: DIAMOX Sodium 500mg Powder for Solution for Injection, Acetazolamide 500mg Powder for Solution for Injection
  6. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    [A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

    Products: BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL
  7. Drug

    Simoctocog alfa

    go.drugbank.com/drugs/DB09108
    Approved

    As patients with haemophilia A are predisposed to episodes of recurrent bleeding [L1115], simoctocog alfa can be administered for the treatment or prevention of bleeding such as prior to surgical procedures

    Products: Nuwiq 250IU Powder for Solution for Injection, Nuwiq 500IU Powder for Solution for Injection
  8. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). … [L15351,A216871] Risdiplam was approved by the FDA in August 2020 for the treatment of spinal muscular atrophy (SMA).

    Products: EVRYSDI POWDER FOR ORAL SOLUTION 0.75 MG/ML, Evrysdi Powder for oral solution 0.75 mg/mL
  9. Drug

    Toll-like receptor 9

    go.drugbank.com/drugs/DB15320
    Investigational

    Toll-like receptor 9 is under investigation in clinical trial NCT03007732 (Pembrolizumab in Combination With Intratumoral SD-101 Therapy).

    Categories: Toll-Like Receptor 9, agonistsSynonyms: Toll-like receptor 9
  10. Drug

    Canakinumab

    go.drugbank.com/drugs/DB06168
    ApprovedInvestigational

    both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). … Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are

    Products: Ilaris Powder for Solution for Injection 150mg/vial, ILARIS 150MG POWDER FOR SOLUTION FOR INJECTION